Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCVNAT donor screening in Australia and the implications for future HBVNAT

被引:67
作者
Seed, CR [1 ]
Cheng, A [1 ]
Ismay, SL [1 ]
Bolton, WV [1 ]
Kiely, P [1 ]
Cobain, TJ [1 ]
Keller, AJ [1 ]
机构
[1] Australian Red Cross Blood Serv, Perth, WA 6000, Australia
关键词
D O I
10.1046/j.1537-2995.2002.00204.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Risk modeling is now the most practical method of estimating the residual risk of viral transmission in developed countries. One method of assessing the accuracy of a risk model is to measure the observed against the predicted outcome after implementing a new screening method. The primary objective of this paper is to assess the accuracy of three published models in predicting the impact of implementing HIV and HCV NAT in Australia. STUDY DESIGN AND METHODS: Viral screening data on Australian donors for 2000 and 2001 were retrospectively analyzed. The data were applied to the three models to estimate the risk of transmission and predicted NAT yield for HIV, HCV, and HBV. RESULTS: The median risk estimates for the three models were 1 in 3,415,000 for HIV NAT, 1 in 911,000 for HCV NAT, and 1 in 483,000 for HBsAg. The predicted NAT yield for the three models ranged from 0.17 to 0.30 per million donations for HIV, 1.20 to 5.55 for HCV, and 0.47 to 1.01 for HBV. The observed NAT yield was not significantly different from the expected yield with any of the three models for either HIV or HCV. CONCLUSIONS: First, the residual risk in Australian donors is small in comparison with other transfusion complications and comparable to or lower than the risk in US and European nonremunerated donors. Second, mathematical risk modeling has sufficient precision to be used as a predictive tool for risk-benefit assessments of novel screening procedures. Finally, in relation to the case for implementing HBV NAT and/or anti-HBc in Australia, we conclude that at present, there is inadequate information about our donor population to perform an evidence-based risk-benefit analysis.
引用
收藏
页码:1365 / 1372
页数:8
相关论文
共 35 条
[1]   Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion [J].
Allain, JP ;
Hewitt, PE ;
Tedder, RS ;
Williamson, LM .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) :186-195
[2]  
Biswas R, 2001, TRANSFUSION, V41, p8S
[3]   POSTTRANSFUSION HEPATITIS - IMPACT OF NON-A, NON-B-HEPATITIS SURROGATE TESTS [J].
BLAJCHMAN, MA ;
BULL, SB ;
FEINMAN, SV .
LANCET, 1995, 345 (8941) :21-25
[4]  
Busch MP, 2001, BLOOD SAFETY IN THE NEW MILLENNIUM, P33
[5]   TIME-COURSE OF DETECTION OF VIRAL AND SEROLOGIC MARKERS PRECEDING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SEROCONVERSION - IMPLICATIONS FOR SCREENING OF BLOOD AND TISSUE DONORS [J].
BUSCH, MP ;
LEE, LLL ;
SATTEN, GA ;
HENRARD, DR ;
FARZADEGAN, H ;
NELSON, KE ;
READ, S ;
DODD, RY ;
PETERSEN, LR .
TRANSFUSION, 1995, 35 (02) :91-97
[6]   DECREASE IN REPORTED POSTTRANSFUSION HEPATITIS - CONTRIBUTIONS OF DONOR SCREENING FOR ALANINE AMINOTRANSFERASE AND ANTIBODIES TO HEPATITIS-B CORE ANTIGEN AND CHANGES IN THE GENERAL-POPULATION [J].
CHAMBERS, LA ;
POPOVSKY, MA .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (12) :2445-2448
[7]   Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies [J].
Correll, PK ;
Law, MG ;
Seed, CR ;
Gust, A ;
Buring, M ;
Dax, EM ;
Keller, AJ ;
Kaldor, JM .
VOX SANGUINIS, 2001, 81 (01) :6-11
[8]  
Grob P, 2000, J MED VIROL, V62, P450, DOI 10.1002/1096-9071(200012)62:4&lt
[9]  
450::AID-JMV9&gt
[10]  
3.0.CO